AdaptHealth Corp. (AHCO) stock
Close on Nov 17, 2026Market cap $1.03BP/E –Yield –
Earnings
AdaptHealth's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of AdaptHealth's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 23, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026before the open | $745.60M | -9.1% | -$1.13 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026before the open | $740.30M | -7.5% | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026before the open | $819.80M | +5.4% | -$0.12 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026before the open | $846.30M | -1.2% | -$0.76 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025before the open | $820.30M | +1.8% | $0.16 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $800.40M | -0.7% | $0.10 | $0.10 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025before the open | $777.90M | -1.8% | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025before the open | $856.60M | -0.2% | $0.34 | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 5, 2024before the open | $805.90M | +0.2% | $0.15 | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $806.00M | +1.6% | $0.13 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024before the open | $792.50M | +6.4% | -$0.02 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024before the open | $858.20M | +10.0% | -$1.91 | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023before the open | $804.00M | +6.3% | -$3.43 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $793.30M | +9.0% | $0.09 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023before the open | $744.60M | +5.4% | -$0.06 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 27, 2023after the close | $780.30M | +11.1% | -$0.02 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | $756.50M | +15.8% | $0.11 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022before the open | $727.60M | – | $0.09 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022before the open | $706.20M | – | $0.08 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022before the open | $702.10M | – | $0.15 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $653.30M | – | $0.20 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 4, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
AdaptHealth's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Net revenueGAAP | FY2026 | $2.88B – $2.90B | – | New | Nov 3, 2026 |
| Net revenue | FY2026 | $2.85B – $2.89B | $3.45B – $3.52B | Lowered | Aug 4, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $510.00M – $525.00M | – | New | Nov 3, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $490.00M – $520.00M | $680.00M – $730.00M | Lowered | Aug 4, 2026 |
| Free cash flownon-GAAP | FY2026 | $50.00M – $75.00M | – | New | Nov 3, 2026 |
| Free cash flownon-GAAP | FY2026 | $80.00M – $120.00M | $175.00M – $225.00M | Lowered | Aug 4, 2026 |
Guidance vs results
The last range AdaptHealth gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $3.18B – $3.26B | $3.24BΣ4Q | Within range |
Guidance history
Every forecast AdaptHealth put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 3, 2026 | Adjusted EBITDA | FY2026 | $510.00M – $525.00M | New |
| Nov 3, 2026 | Free cash flow | FY2026 | $50.00M – $75.00M | New |
| Nov 3, 2026 | Net revenue | FY2026 | $2.88B – $2.90B | New |
| Aug 4, 2026 | Adjusted EBITDA | FY2026 | $490.00M – $520.00M | Lowered |
| Aug 4, 2026 | Free cash flow | FY2026 | $80.00M – $120.00M | Lowered |
| Aug 4, 2026 | Net revenue | FY2026 | $2.85B – $2.89B | Lowered |
| May 5, 2026 | Adjusted EBITDA | FY2026 | $680.00M – $730.00M | Reaffirmed |
| May 5, 2026 | Free cash flow | FY2026 | $175.00M – $225.00M | Reaffirmed |
| May 5, 2026 | Net revenue | FY2026 | $3.45B – $3.52B | Raised |
| Feb 24, 2026 | Adjusted EBITDA | FY2026 | $680.00M – $730.00M | New |
| Feb 24, 2026 | Free cash flow | FY2026 | $175.00M – $225.00M | New |
| Feb 24, 2026 | Net revenue | FY2026 | $3.44B – $3.51B | New |
| Nov 4, 2025 | Adjusted EBITDA | FY2025 | $642.00M – $682.00M | New |
| Nov 4, 2025 | Free cash flow | FY2025 | $170.00M – $190.00M | New |
| Nov 4, 2025 | Net revenue | FY2025 | $3.18B – $3.26B | New |
| Aug 5, 2025 | Adjusted EBITDA | FY2025 | $642.00M – $682.00M | Lowered |
| Aug 5, 2025 | Free cash flow | FY2025 | $170.00M – $190.00M | Lowered |
| Aug 5, 2025 | Net revenue | FY2025 | $3.18B – $3.26B | Lowered |
| May 6, 2025 | Adjusted EBITDA | FY2025 | $665.00M – $705.00M | Lowered |
| May 6, 2025 | Free cash flow | FY2025 | $180.00M – $220.00M | Reaffirmed |
| May 6, 2025 | Net revenue | FY2025 | $3.18B – $3.32B | Lowered |
| Feb 25, 2025 | Adjusted EBITDA | FY2025 | $670.00M – $710.00M | New |
| Feb 25, 2025 | Free cash flow | FY2025 | $180.00M – $220.00M | New |
| Feb 25, 2025 | Net revenue | FY2025 | $3.22B – $3.36B | New |
| Nov 5, 2024 | Adjusted EBITDA | FY2024 | $655.00M – $675.00M | Lowered |
| Nov 5, 2024 | Free cash flow | FY2024 | $175.00M – $195.00M | Raised |
| Nov 5, 2024 | Net revenue | FY2024 | $3.22B – $3.26B | New |
| Aug 6, 2024 | Adjusted EBITDA | FY2024 | $660.00M – $700.00M | Narrowed |
| Aug 6, 2024 | Free cash flow | FY2024 | $160.00M – $180.00M | Raised |
| Aug 6, 2024 | Net revenue | FY2024 | $3.26B – $3.32B | Narrowed |
| Feb 27, 2024 | Adjusted EBITDA | FY2024 | $650.00M – $710.00M | New |
| Feb 27, 2024 | Free cash flow | FY2024 | $150.00M – $180.00M | New |
| Feb 27, 2024 | Net revenue | FY2024 | $3.25B – $3.35B | New |
| Nov 7, 2023 | Total capital expenditures | FY2023 | 10% – 12% | Reaffirmed |
| Nov 7, 2023 | Adjusted EBITDA | FY2023 | $630.00M – $650.00M | Lowered |
| Nov 7, 2023 | Free cash flow | FY2023 | 3% – 4% | Reaffirmed |
| Nov 7, 2023 | Net revenue | FY2023 | $3.16B – $3.19B | Lowered |
| Aug 8, 2023 | Total capital expenditures | FY2023 | 10% – 12% | New |
| Aug 8, 2023 | Adjusted EBITDA | FY2023 | $650.00M – $680.00M | Lowered |
| Aug 8, 2023 | Free cash flow | FY2023 | 3% – 4% | New |
| Aug 8, 2023 | Net revenue | FY2023 | $3.16B – $3.20B | Lowered |
| Feb 27, 2023 | Total capital expenditures | FY2023 | 10% – 12% | New |
| Feb 27, 2023 | Adjusted EBITDA | FY2023 | $650.00M – $710.00M | New |
| Feb 27, 2023 | Net revenue | FY2023 | $3.16B – $3.24B | New |
| Nov 8, 2022 | Total capital expenditures | FY2022 | 10% – 12% | Raised |
| Nov 8, 2022 | Adjusted EBITDA | FY2022 | $620.00M – $650.00M | Narrowed |
| Nov 8, 2022 | Net revenue | FY2022 | $2.95B – $3.01B | Narrowed |
| Aug 9, 2022 | Total capital expenditures | FY2022 | 9% – 11% | Reaffirmed |
| Aug 9, 2022 | Adjusted EBITDA | FY2022 | $615.00M – $675.00M | Reaffirmed |
| Aug 9, 2022 | Net revenue | FY2022 | $2.84B – $3.04B | Reaffirmed |
| May 10, 2022 | Total capital expenditures | FY2022 | 9% – 11% | Reaffirmed |
| May 10, 2022 | Adjusted EBITDA | FY2022 | $615.00M – $675.00M | Raised |
| May 10, 2022 | Net revenue | FY2022 | $2.84B – $3.04B | Raised |
| Feb 24, 2022 | Total capital expenditures | FY2022 | 9% – 11% | New |
| Feb 24, 2022 | Adjusted EBITDA | FY2022 | $610.00M – $670.00M | Lowered |
| Feb 24, 2022 | Net revenue | FY2022 | $2.83B – $3.03B | Raised |
| Nov 4, 2021 | Total capital expenditures | FY2022 | 9% – 11% | New |
| Nov 4, 2021 | Adjusted EBITDA | FY2021 | $570.00M – $580.00M | New |
| Nov 4, 2021 | Adjusted EBITDA | FY2022 | $635.00M – $695.00M | New |
| Nov 4, 2021 | Adjusted EBITDA less Patient Equipment Capex | FY2021 | $365.00M – $375.00M | New |
| Nov 4, 2021 | Net revenue | FY2021 | $2.41B – $2.46B | New |
| Nov 4, 2021 | Net revenue | FY2022 | $2.70B – $2.90B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases AdaptHealth filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Update
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Update
- Update
See a number that looks wrong?